Phase-III Trial Panorama

Phase III clinical study on the efficacy and safety of MM-120

(LSD-D-tartrate) in the treatment of Generalized Anxiety Disorder (Panorama)

Starting in August 2025, we will participate as a study center in a clinical trial using MM-120 (LSD-D-tartrate).

What is the study about?

The study will investigate the efficacy and safety of the psychedelic drug MM-120 in the treatment of Generalized Anxiety Disorder in adult patients compared to placebo.

Who is conducting the study?

This is a Phase III clinical trial conducted by MindMed (America), in which approximately 35 study centers worldwide are participating.

Course of the clinical trial:

Up to 360 participants worldwide will be able to participate in the study. Participation in the study will last at least 12 weeks and can be voluntarily extended to a total period of up to one year.

The study comprises several phases, some of which can be completed on-site at the OVID Clinic or partially remotely from home.

These include:

Screening phase (max. 4 weeks) with one visit at the clinic
Core study (12 weeks) with a preparatory visit, one dosing session (either placebo, 50 µg, or 100 µg MM-120), and seven follow-up visits
Open-label phase (voluntary, up to 40 weeks) with monthly visits and up to four additional dosing sessions with 100 µg MM-120

In the core study, some participants receive the active substance, while others receive a placebo. In both cases, eligible participants can voluntarily participate in an Open Label Extension (OLE), which includes up to four additional dosing sessions with the test substance (100 µg) within one year.

Information on the inclusion criteria

Patients between 18 and 74 years of age are eligible to participate in the study if they:

Primarily suffer from Generalized Anxiety Disorder
Are willing to discontinue their current psychiatric medication
Are able to attend regular visits at the OVID Clinic for at least 12 weeks
Are willing to use an adequate form of contraception over the course of the study

Information on the exclusion criteria

Applicants who meet the following criteria are not eligible to participate in the study:

Presence of certain psychiatric disorders (except Generalized Anxiety Disorder)
Presence of a psychotic or bipolar disorder in a first-degree relative (parent, sibling)
Current diagnosis of an alcohol or substance use disorder (except caffeine and nicotine)
Presence of an acute or chronic, unstable, or untreated clinically significant illness